Palatin Tech Stock Price, News & Analysis

Palatin Technologies (NYSE American: PTN) will announce its Q3 fiscal year 2021 operating results on May 17, 2021, before the U.S. markets open. A conference call, led by the executive management team, is scheduled for the same day at 11:00 a.m. ET to discuss the results and provide updates on ongoing programs. The results will be released at 7:30 a.m. ET.

Investors can access the audio webcast and replay through the Investors-Webcasts section on the company's website.

Palatin Technologies (PTN) announced that the USPTO granted a 5-year patent term extension for one of its patents covering Vyleesi® (bremelanotide injection), now set to expire on June 25, 2025. Vyleesi is the only FDA-approved on-demand treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women. The extension is in line with the Hatch-Waxman Amendments, compensating for time lost during drug development and FDA review. Additional patents related to methods of treating HSDD are valid until November 2033.

Palatin Technologies, Inc. (NYSE American: PTN) announced two presentations at the virtual ARVO 2021 Annual Meeting, occurring from May 1-7, 2021. The presentations will showcase clinical data for PL9643, a melanocortin agonist, focusing on its potential in treating dry eye disease and ocular inflammation. CEO Carl Spana emphasized the therapeutic promise of melanocortins in inflammatory conditions during the event. Presentations are set for May 1 and May 6, covering efficacy and safety studies and protective effects in ocular disease models, respectively.

Palatin Technologies (NYSE American: PTN) will participate in the H.C. Wainwright Global Life Sciences Virtual Conference on March 9-10, 2021. CEO Carl Spana will present, with the presentation available for on-demand viewing starting March 9, 2021, at 7:00 a.m. ET. It will remain accessible on Palatin's Investor page for 30 days. The company focuses on developing first-in-class medicines targeting melanocortin peptide receptor systems, addressing significant medical needs.

Palatin Technologies (PTN) reported a net loss of $10.0 million, or $0.04 per share, for the second quarter ended December 31, 2020, compared to a loss of $5.2 million, or $0.02 per share, in Q2 2019. The increase in loss is primarily due to commercial expenses for Vyleesi and ongoing Phase 2 trials for PL9643. Vyleesi gross sales reached $943,950, with product revenue at -$163,971. However, the company announced positive results for PL9643 in treating dry eye disease, with the next Phase 2/3 trial set for mid-2021.

Palatin Technologies (NYSE American: PTN) will announce its Q2 fiscal year 2021 operating results on February 17, 2021, before the U.S. financial markets open. A conference call will follow at 11:00 a.m. ET to discuss the results and provide updates on development programs. Interested parties can access the audio webcast through Palatin's website. The company focuses on developing targeted peptide therapeutics for significant unmet medical needs and seeks to establish collaborations to maximize the commercial potential of its products.

Palatin Technologies (NYSE American: PTN) announced the filing of an international patent application for PL9643, aimed at treating Dry Eye Disease (DED). Positive Phase 2 study results will be shared at the ARVO 2021 meeting, with a Phase 2/3 trial planned for mid-2021. If granted, the patent could protect PL9643 until 2041. Dry Eye Disease affects over 20 million Americans, causing significant discomfort and potential vision issues. Palatin aims to develop first-in-class medicines targeting unmet medical needs, seeking partnerships to enhance commercialization efforts.

Palatin Technologies (PTN) announced positive results from its Phase 2 study of PL9643 for treating moderate to severe dry eye disease (DED). The trial showed significant improvement in multiple ocular signs and symptoms after 2 weeks and at the 12-week mark for the specific moderate to severe patient population, although overall primary endpoints were not met. No safety issues arose, and PL9643 demonstrated excellent ocular tolerability. Palatin plans to advance to a Phase 2/3 trial in mid-2021, targeting the approximately 20 million adults suffering from DED in the U.S.

Palatin Technologies, Inc. (PTN) reported a net loss of $3.9 million for Q1 2020, down from $4.5 million in Q1 2019. Vyleesi® gross sales reached $809,100, with recognized revenue of $(288,560). Total operating expenses decreased to $3.7 million. The company had $86.6 million in cash and equivalents as of September 30, 2020. Palatin regained North American rights to Vyleesi, enhancing commercial activities and initiating a targeted marketing campaign. Upcoming data readout for PL9643 Phase 2 clinical trial is expected in December 2020.